Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection (“Flesh-Eating Disease”)
11th December 2020
Portfolio
This post references, or is about AtoxBio. Find out more by clicking below
Print Article
Email Article
Save Article
Stay Updated
Add your email below to stay updated with useful and informative content from Arix and our portfolio companies
